50 related articles for article (PubMed ID: 20477500)
1. The HOXB13:IL17BR gene-expression ratio: a biomarker providing information above and beyond tumor grade.
Sgroi DC
Biomark Med; 2009 Apr; 3(2):99-102. PubMed ID: 20477500
[No Abstract] [Full Text] [Related]
2. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.
Jansen MP; Sieuwerts AM; Look MP; Ritstier K; Meijer-van Gelder ME; van Staveren IL; Klijn JG; Foekens JA; Berns EM
J Clin Oncol; 2007 Feb; 25(6):662-8. PubMed ID: 17308270
[TBL] [Abstract][Full Text] [Related]
3. Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcome.
Jerevall PL; Brommesson S; Strand C; Gruvberger-Saal S; Malmström P; Nordenskjöld B; Wingren S; Söderkvist P; Fernö M; Stål O
Breast Cancer Res Treat; 2008 Jan; 107(2):225-34. PubMed ID: 17453342
[TBL] [Abstract][Full Text] [Related]
4. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.
Ma XJ; Hilsenbeck SG; Wang W; Ding L; Sgroi DC; Bender RA; Osborne CK; Allred DC; Erlander MG
J Clin Oncol; 2006 Oct; 24(28):4611-9. PubMed ID: 17008703
[TBL] [Abstract][Full Text] [Related]
5. The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer.
Wang Z; Dahiya S; Provencher H; Muir B; Carney E; Coser K; Shioda T; Ma XJ; Sgroi DC
Clin Cancer Res; 2007 Nov; 13(21):6327-34. PubMed ID: 17975144
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma.
Okuda H; Toyota M; Ishida W; Furihata M; Tsuchiya M; Kamada M; Tokino T; Shuin T
Oncogene; 2006 Mar; 25(12):1733-42. PubMed ID: 16278676
[TBL] [Abstract][Full Text] [Related]
7. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
8. Limits of predictive models using microarray data for breast cancer clinical treatment outcome.
Reid JF; Lusa L; De Cecco L; Coradini D; Veneroni S; Daidone MG; Gariboldi M; Pierotti MA
J Natl Cancer Inst; 2005 Jun; 97(12):927-30. PubMed ID: 15956654
[TBL] [Abstract][Full Text] [Related]
9. Regulation of tumor invasion by HOXB13 gene overexpressed in human endometrial cancer.
Zhao Y; Yamashita T; Ishikawa M
Oncol Rep; 2005 Apr; 13(4):721-6. PubMed ID: 15756448
[TBL] [Abstract][Full Text] [Related]
10. HOXB13 homeodomain protein is cytoplasmic throughout fetal skin development.
Kömüves LG; Ma XK; Stelnicki E; Rozenfeld S; Oda Y; Largman C
Dev Dyn; 2003 Jun; 227(2):192-202. PubMed ID: 12761847
[TBL] [Abstract][Full Text] [Related]
11. HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling.
Jung C; Kim RS; Zhang HJ; Lee SJ; Jeng MH
Cancer Res; 2004 Dec; 64(24):9185-92. PubMed ID: 15604291
[TBL] [Abstract][Full Text] [Related]
12. Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to affect cell growth in AR-negative prostate cancers.
Ren G; Zhang G; Dong Z; Liu Z; Li L; Feng Y; Su D; Zhang Y; Huang B; Lu J
Int J Biochem Cell Biol; 2009 May; 41(5):1094-101. PubMed ID: 19013255
[TBL] [Abstract][Full Text] [Related]
13. Predicting features of breast cancer with gene expression patterns.
Lu X; Lu X; Wang ZC; Iglehart JD; Zhang X; Richardson AL
Breast Cancer Res Treat; 2008 Mar; 108(2):191-201. PubMed ID: 18297396
[TBL] [Abstract][Full Text] [Related]
14. Intratumor heterogeneity of biomarker expression in breast carcinomas.
Chhieng DC; Frost AR; Niwas S; Weiss H; Grizzle WE; Beeken S
Biotech Histochem; 2004 Feb; 79(1):25-36. PubMed ID: 15223751
[TBL] [Abstract][Full Text] [Related]
15. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.
Lusis EA; Watson MA; Chicoine MR; Lyman M; Roerig P; Reifenberger G; Gutmann DH; Perry A
Cancer Res; 2005 Aug; 65(16):7121-6. PubMed ID: 16103061
[TBL] [Abstract][Full Text] [Related]
16. Expression of Hoxb13 and Hoxc10 in developing and regenerating Axolotl limbs and tails.
Carlson MR; Komine Y; Bryant SV; Gardiner DM
Dev Biol; 2001 Jan; 229(2):396-406. PubMed ID: 11150241
[TBL] [Abstract][Full Text] [Related]
17. Expression of oligodendrocytic mRNAs in glial tumors: changes associated with tumor grade and extent of neoplastic infiltration.
Landry CF; Verity MA; Cherman L; Kashima T; Black K; Yates A; Campagnoni AT
Cancer Res; 1997 Sep; 57(18):4098-104. PubMed ID: 9307299
[TBL] [Abstract][Full Text] [Related]
18. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
[TBL] [Abstract][Full Text] [Related]
19. Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer.
Takihana Y; Tsuchida T; Fukasawa M; Araki I; Tanabe N; Takeda M
Int J Urol; 2006 Apr; 13(4):401-8. PubMed ID: 16734859
[TBL] [Abstract][Full Text] [Related]
20. Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers.
Kakehi Y; Wu WJ; Kim WJ; Arao S; Fukumoto M; Yoshida O
Int J Urol; 1995 Nov; 2(5):309-15. PubMed ID: 8749949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
